Capricor Therapeutics is trading 5.09% up now at $10.52 after Piper Sandler upgraded the shares to Overweight from Neutral and raised its price target to $25 from $2.
- FDA acceptance of a major Deramiocel BLA amendment includes 24-month HOPE-3 extension data and additional analyses.
- The stock is extending a strong late-August rally, while biotech-sector strength provides additional support.